The 2 Best Nuclear Energy Stocks to Buy in April

The article argues that rising AI power demand and a global nuclear buildout are improving the investment case for uranium and SMR-related stocks. Cameco reported 2025 revenue growth of 11% and EPS growth of 246%, while BWX Technologies posted 2025 revenue of $3.19 billion, up 18%, with EPS up 20%. The piece is broadly bullish on nuclear energy exposure, but it is primarily commentary rather than new company-specific news.

Analysis

The market is still pricing nuclear as a thematic trade, but the more durable edge is in bottlenecks, not headline reactor counts. The real second-order winner is the fuel cycle and project-enablement layer: if buildout accelerates, uranium volumes matter less near term than conversion, enrichment, fabrication, and maintenance capacity, where lead times can stretch for years and pricing is far less elastic. That makes vertically integrated exposure more defensible than pure miners, while also raising the odds of margin expansion from scarcity rather than demand alone.

CCJ benefits from having multiple toll booths across the chain, which reduces the risk that a spot uranium pullback meaningfully dents earnings. The more interesting setup is that reactor deployment enthusiasm can outpace actual fuel burn for a long time, so the stock can continue to rerate on order-book visibility even before the physical market tightens. The main reversal risk is policy-induced: a delay in permitting, financing, or cost overruns at large Western builds could cool sentiment faster than commodity fundamentals deteriorate.

BWXT is a different kind of asset: less about a near-term SMR breakthrough and more about optionality on a regulated, defense-adjacent industrial franchise that can monetize any nuclear normalization. The hidden catalyst is that data-center power demand could pull capital toward modular, behind-the-meter solutions, but actual commercialization is a multi-year story and the equity likely trades on milestones rather than revenue today. Consensus may be underestimating how much of BWXT’s value can be defended even if SMRs slip, because the core naval business provides earnings support while investors pay for call options on land-based reactors.

Contrarian view: the crowd may be overpaying for simple uranium beta while underpricing execution risk in SMRs. If the trade becomes crowded, a short-duration unwind could hit CCJ harder than BWXT, since CCJ has already re-rated substantially and is more exposed to sentiment around commodity scarcity. The cleaner expression is to own the highest-quality balance sheet and project leverage, not the purest narrative exposure.

Key Decisions for Investors

• Long CCJ on pullbacks over the next 1-3 months; target a 12-18 month hold. Favor it as a lower-risk way to own the nuclear supply chain, but size modestly because the stock has already de-risked a lot of good news.
• Long BWXT as a 12-24 month options-like equity exposure to SMR adoption. Best entry is on any weakness tied to delayed SMR headlines, since the core defense/naval business should cushion downside.
• Pair trade: long BWXT / short a basket of pre-revenue or early-stage SMR developers for 6-12 months. This captures the theme while avoiding binary commercialization risk and should outperform if the sector reprices toward execution quality.
• Use call spreads on CCJ rather than outright stock if adding now. The risk/reward is better if uranium sentiment remains strong but mean reversion in a crowded trade limits upside.
• Watch for any policy or financing delays in Western nuclear projects; if those emerge, trim CCJ first and keep BWXT longer because its earnings base is less dependent on near-term reactor completion.